Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $25.00 | Buy | Guggenheim |
| 1/5/2023 | $54.00 | Sector Outperform | Scotiabank |
| 1/7/2022 | $59.00 | Overweight | Stephens & Co. |
| 11/9/2021 | $85.00 → $75.00 | Outperform | SVB Leerink |
| 7/14/2021 | $80.00 → $85.00 | Outperform | SVB Leerink |
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette. The designation is based exclusively on anonymous employee feedback gathered through a third-party survey. The confidential survey measures several aspects of workplace culture designed to be indicative of employee satisfaction and engagement, including feeling respected and supported, enabled to grow and empowered to execute. "This recognition belongs to our employees, whose voices and feedback shape the cu
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America's Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics. "This recognition from Newsweek underscores the power of our commitment to ‘put people first' in everything we do, from pioneering molecular tests that may improve patient outcomes, to building a culture that
FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its TissueCypher Barrett's Esophagus test will be shared via a podium presentation at the American Foregut Society's (AFS) 2025 Annual Meeting, taking place Sept. 11-13, 2025, in Dallas. "The findings being presented at AFS underscore the importance of moving beyond standard pathology when assessing progression risk in patients with Barrett's esophagus," said lead study author Caitlin C. Houghton, M.D., board-certified foregut s
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast
Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00
Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00
Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful